facebook

For adults and children with hemophilia A

REACH HIGHER With the Long-lasting
Protection of AFSTYLA

The first and only recombinant Factor VIII that delivers proven, long-lasting bleed protection with a novel single-chain design.

2 times weekly

AFSTYLA offers dosing 2 or 3 times a week so you and your doctor have more flexibility in choosing a schedule that works for you.

Twice-weekly dosing available

FDA-approved for dosing 2 or 3 times a week.

Learn about AFSTYLA dosing

Zero bleeds  (median AsBR*)

Zero median annualized spontaneous bleeds* were reported in both children and adults regardless of dosing schedule (2 or 3 times a week).

ZERO bleeds (median AsBR*)

In clinical trials, whether dosed 2 or 3 times a week.

Explore AFSTYLA protection

*Annualized spontaneous bleeding rate in clinical trials (interquartile range [IQR]=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).

Factor VIII

AFSTYLA uses a novel single-chain design to enhance molecular stability in the bloodstream and provide long-lasting bleed protection.

Comparable to natural Factor VIII

Once activated, AFSTYLA is identical to natural Factor VIII.

Learn how AFSTYLA works

*Annualized spontaneous bleeding rate in clinical trials(interquartile range [IQR]=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).

Get your free AFSTYLA Discovery Kit

Sign up today

Email address

Switching to AFSTYLA is as easy as 1-2-3

Thinking about switching to AFSTYLA from another Factor VIII product?

CSL Behring makes it easy to start on AFSTYLA with a simple 3-step process. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.

You can also call 1-800-676-4266 to get detailed information about the services available to you.

See how to switch

You are now leaving the current website.

Do you want to continue?

No Yes